Translational Science Techniques

Researchers at Johns Hopkins University have created a revolutionary protein “switch” that tricks cancer cells into manufacturing their own chemotherapy drugs, causing them to self-destruct while sparing healthy cells. Instead of delivering drugs directly to cancer cells, this method uses a harmless “prodrug” that only becomes activated inside cancer cells when the switch detects specific cancer markers. The switch is made by combining two proteins: one that senses cancer markers and another from yeast that converts the inactive prodrug into a potent cancer-killing drug. When the switch detects cancer, it activates the drug inside that cell, turning the cancer cell into a drug factory that destroys itself. To work, the switch must enter cancer cells either by delivering the protein itself or by inserting the gene that makes the protein, allowing the cancer cell’s own machinery to produce the switch. Afterward, patients receive the inactive chemotherapy prodrug, which becomes activated only inside cancer cells. This new approach focuses on producing the drug inside cancer cells rather than just delivering it to them, which could kill more cancer cells while reducing harmful side effects on healthy tissue. Lab tests on human colon and breast cancer cells have shown promise, and animal testing is expected to start within a year. While still early, this technique offers a radically different way to attack cancer. #PNAS #RMScienceTechInvest

How can we decrease pharmacy spend on high-cost drugs by double digits without worse outcomes? --- Uplift modeling is a common tactic in marketing to target the specific people for a promotion that otherwise wouldn’t buy the product. While marketing in general can lead to overconsumption, in healthcare/#pharmacy, the same mathematical techniques used for uplift modeling could be repurposed to support #PrecisionMedicine or personalized medicine, where the goal is to identify which patients are most likely to benefit from a specific treatment while avoiding unnecessary treatments for patients who might not respond well. Identifying the cohort that is getting most of the outcomes from a drug varies by drug, but some drugs have only a fraction of the total population driving a larger share of clinical results. --- Here's the basic process for using #UpliftModeling (you can find more details from my Milliman white paper in the comments): 1. Treatment: Identify the treatment for which you want to predict response (e.g., a high-cost brand/specialty drug like GLP-1s). This could also be done for a medical device or any intervention. 2. Data collection: Gather comprehensive data and studies about patients, including their medical history, genetic information, and any other relevant attributes. This is often the limiter of building a good model. 3. Control group: Assemble a control group of patients who are similar to those receiving the treatment but are not receiving the treatment themselves. This helps establish a baseline for comparison. 4. Outcome measurement: Measure the effectiveness of the treatment for both the treatment group and the control group. This could involve monitoring health improvements, cardiac events, or other relevant medical outcomes. For FDA-approved drugs, this could come from published research on the “absolute risk reduction” or “number needed to treat.” 5. Model building: Develop predictive models using machine learning algorithms that estimate the likelihood of a positive response to the treatment for each individual. 6. Uplift calculation: Calculate the difference in response rates between the treatment group and the control group to determine the net impact of the treatment. 7. Segment: Divide patients into different segments based on their predicted response probabilities. 8. Action: Use the insights from uplift modeling to guide treatment, coverage, or other decisions. --- A payer or employer can use this information how they’d like, but I imagine it will be used to adjust formularies or utilization management strategies. It could also be used when setting up contracts for how a drug should be used while carving out certain drugs or disease states (e.g. oncology drugs at a center of excellence). There are more potential use cases in the white paper in the comments. --- Would you use this strategy for #PharmacyBenefits or #ValueBasedCare models that take on risk for cost of care?

A New Chapter in Cancer Therapy: RIPTACs The Debut of a New Modality in the Clinic In February 2025, Halda Therapeutics began clinical trials for HLD-0915, the first-in-class RIPTAC - Regulated Induced Proximity Targeting Chimeras. * * What are RIPTACs? These bifunctional small molecules don’t inhibit enzymes or degrade proteins like PROTACs do - they just disable activity of cancer cell after binding to two proteins: a tumor marker and another that is functionally essential, both inside cell. Bringing two proteins into close proximity — incl blocking of activity of essential enzyme is what triggers cell inactivation. The result? Selective killing of cancer cells, without touching healthy tissues. 🌟 Key Points + Tissue-specific targeting: Kills only cells that co-express both proteins — a leap toward precision oncology. + No need for degradation or inhibition: A novel mechanism avoids current resistance pitfalls. + Modularity: In theory, RIPTACs can be adapted across various cancer types using different protein pairs. Is it a breakthrough? Yes. RIPTACs represent a next-generation approach in cancer therapy that differs fundamentally from chemotherapy and PROTACs. With their broader therapeutic window and potential for finely tuned selectivity, RIPTACs could surpass both in precision, safety, and adaptability. There are interesting potential applications in regenerative medicine as well. 🔗 Nature Reviews Drug Discovery 24, 235–237 (2025) #RIPTAC #CancerTherapy #BiotechInnovation #ProteinProximity #HaldaTherapeutics #DrugDiscovery #PrecisionOncology #SpiroChem #NextGenTherapeutics

Scientists at the Icahn School of Medicine at Mount Sinai have reported a striking new #immunotherapy approach that challenges how we think about treating metastatic solid #cancers. Rather than targeting cancer cells directly, the team focused on dismantling the #tumor’s immune shield, namely the supportive cells that protect cancer from immune attack. ▫️ Published in Cancer Cell, the study tested this strategy in aggressive preclinical models of metastatic #lungcancer and #ovariancancer, two diseases that have historically been resistant to existing immunotherapies. The key obstacle, the researchers note, is the tumor microenvironment, a highly immunosuppressive “fortress” built largely by tumor-associated macrophages. ▫️Led by Jaime Mateus-Tique, PhD and senior author Brian Brown, PhD, the team engineered #CARTcells to target these tumor macrophages instead of cancer cells themselves. Crucially, the CAR-T cells were further armored to locally release interleukin-12 (IL-12), a potent immune-activating cytokine. ▫️The result was elimination or reprogramming of tumor macrophages, reversal of immune suppression, and recruitment of endogenous killer T cells into the tumor. In mouse models, this led to durable tumor control, prolonged survival, and complete cures in many cases. Advanced spatial genomics confirmed a fundamental reshaping of the tumor microenvironment from immune-silent to immune-active. ▫️The authors emphasize that this is proof of concept rather than a clinical cure, and that human studies are needed to establish safety and efficacy. Ongoing work is focused on refining control of IL-12 delivery to maximize benefit while minimizing toxicity. 💡 This work opens a new path for CAR-T therapies by dismantling the defenses that allow tumors to survive. 🗃️ See comments section for reference

Identifying cancer-related mutations accurately is a critical step in precision medicine. Today, we’ve published new research in Nature Biotechnology on 🧬DeepSomatic🧬, an AI-powered tool that uses machine learning to identify genetic variants, or mutations, in cancer cells more accurately than current methods. This work is aimed at helping researchers pinpoint what's driving a cancer and informing more effective treatment plans. Somatic variant detection is an integral part of cancer genomics analysis. While most methods have focused on short-read sequencing, long-read technologies offer potential advantages to discover variants in the hardest to sequence parts of the genome. 🧬 About the model:  DeepSomatic was rigorously trained on high-confidence data, a feat made possible by working with our partners at UC Santa Cruz. The model is capable of accurately differentiating actual genetic cancer variants from the technical artifacts introduced during sample preservation, addressing a critical hurdle in early detection. 🧬 Superior Accuracy and Clinical Impact:  DeepSomatic consistently outperformed other tools across all major sequencing platforms. It shows major improvements in identifying complex insertions and deletions (Indels). Furthermore, in a new study with partners at Children's Mercy, DeepSomatic successfully found ten small variants in pediatric leukemia cells that were missed by other tools. 🧬 Flexible and Broad Use:  The model is flexible, working across all major sequencing platforms, and can be applied to both tumor-normal and challenging tumor-only samples, extending its utility for complex cancer types. 🧬 Open Access:  We are making DeepSomatic and the CASTLE dataset openly available to the research community. DeepSomatic is the most recent addition to our 10-year journey developing open source methods for geneticists to study the genomes of humans, plants, and animals. We are excited to see how researchers and drug manufacturers will use these resources to develop more effective, personalized treatments for cancer patients. The ability to accurately identify these subtle genetic drivers is key to unlocking new therapies. More in our blog authored by Kishwar Shafin and Andrew Carroll: https://goo.gle/4n23gIB   Read the full article in Nature Biotechnology: https://lnkd.in/drxii8fz

Pretargeted Radiopharmaceutical Therapy: Getting the Vector Right...Then the Payload In Theranostics, the next real leap may not come from a new isotope, but from when and how we deliver it. Pretargeted radiopharmaceutical therapy, also called pretargeted radioimmunotherapy (PRIT) in its antibody-based form, separates biology from physics: a targeting vector first binds the tumor and clears from normal tissues, followed later by a radioactive payload that attaches to the tumor-bound vector. This multi-step workflow improves tumor-to-background ratios, widens the safety window for α-emitters, and redefines what we mean by “precision.” Recent preclinical work, from HER2 bispecific-plus-Ac-225 systems to single-domain antibody platforms, and early human SADA trials show the concept is moving from design to translation. For imaging and therapy professionals, the message is simple: the radionuclide (β, α, or Auger) is only part of the story. The workflow architecture - targeting agent, clearance timing, payload delivery, imaging, and dosimetry - will determine success. The next big breakthrough in Theranostics won’t just come from stronger isotopes, but also from smarter delivery. #MidweekMolecularMatters #Theranostics #RadiopharmaceuticalTherapy #MolecularImaging #Pretargeting #AlphaTherapy #PrecisionOncology BAMF Health (Links in Comments)

💡Resistance to CAR-T Cells: A Scientific Deep Dive CAR-T therapies have transformed hematology, yet resistance and relapse remain major obstacles. The review by Legato et al. (2025, Methods and Protocols) maps in detail how CAR-Ts fail and which strategies may overcome these barriers. 🧬 CAR-T Dysfunction Efficacy depends on the phenotype of infused T cells: • Naïve (TN), stem-cell memory (TSCM), central memory (TCM) → high expansion, persistence. • Effector memory (TEM) and effector (TEff) → short-lived. • Exhausted (TEx) → ↑ PD-1, TIM-3, LAG-3, TIGIT, CTLA-4, with poor cytokine release. • Senescent T cells lose CD27/CD28 and secrete IL-2, IFN-γ but also IL-10, TGF-β. ❗️Aging and prior chemo reduce TSCM pools, impairing product quality. 🎯 Tumor-Intrinsic Resistance The malignant cell adapts rapidly: • Antigen escape: CD19 loss via splicing, promoter methylation, CD81 deletion; BCMA loss via TNFRSF17 mutations; GPRC5D reduced by deletions + hypermethylation. • Trogocytosis: antigen transfer to CAR-Ts → fratricide + exhaustion. • Lineage switch: B-ALL (KMT2A+) shifts to myeloid phenotype. • Genetic lesions: TP53 mutations downregulate Fas/DR5; BCL2 ↑; HLA class I loss + NK checkpoint gene defects → escape from adaptive + innate immunity. ⛔️Tumor Microenvironment (TME) A hostile niche blocks CAR-T function: • Hypoxia → VEGF, PDGF, TGF-β, abnormal vasculature, poor infiltration. • Suppressive cells: Tregs, MDSCs, M2 TAMs. • Cytokines: TGF-β downregulates perforin/granzymes, IL-10 reinforces tolerance. • Metabolites: adenosine, lactate, kynurenine → metabolic acidosis + reduced IFN-γ. • Checkpoints: PD-1/PD-L1 axis reinforced by IFN-γ. In the JULIET trial, high PD-1/PD-L1 colocalization + LAG-3+ T cells correlated with refractory disease. 🦠 Microbiota & Patient Factors • Antibiotics (piperacillin/tazobactam, carbapenems) pre-infusion → ↓ diversity, worse OS, ↑ ICANS. • Protective taxa: Faecalibacterium, Ruminococcus, Bacteroides. • SCFAs improve CAR-T metabolic fitness. 🛠️ Strategies to Overcome Resistance ▪️CAR design: • CD28 vs 4-1BB → rapid expansion vs long persistence. • Low-affinity CARs (obe-cel, CAT-CARs) reduce trogocytosis. • Dual/tri-targeting (CD19/CD22/CD20; BCMA/CD19) lower escape risk. • Armored CARs: secrete IL-12/IL-18 or minibodies blocking PD-1/CTLA-4. • Switch receptors: turn PD-1 or Fas inhibitory signals into CD28/4-1BB activation. • Logic gates: AND/OR/NOT or SynNotch circuits enhance specificity. ▪️Manufacturing: enrich TSCM with IL-7/IL-15, early leukapheresis, fast-CAR platforms (<7d; preclinically <24h). ▪️Allogeneic CAR-T: gene-edited (TCR-/HLA-) off-the-shelf products (UCAR19, ALLO-501). ▪️New effectors: CAR-NKs (lower CRS/ICANS, HLA-independent killing) and CAR-macrophages (antigen spreading + tumor infiltration). #CART #Immunotherapy #Hematology #Oncology #CellTherapy

𝗜𝗺𝗮𝗴𝗶𝗻𝗲 𝗶𝗳 𝗴𝗲𝗻𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗰𝗼𝘂𝗹𝗱 𝗵𝗼𝗺𝗲 𝗶𝗻 𝗼𝗻 𝗼𝗻𝗹𝘆 𝘁𝗵𝗲 𝗰𝗲𝗹𝗹𝘀 𝘄𝗲 𝘄𝗮𝗻𝘁—𝘂𝗻𝗹𝗼𝗰𝗸𝗶𝗻𝗴 𝘁𝗿𝘂𝗲 𝗽𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗮𝗻𝗱 𝗶𝗺𝗽𝗿𝗼𝘃𝗶𝗻𝗴 𝘀𝗮𝗳𝗲𝘁𝘆 𝗳𝗼𝗿 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀. 𝗧𝗵𝗮𝘁 𝗯𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗶𝘀 𝗻𝗼𝘄 𝘄𝗶𝘁𝗵𝗶𝗻 𝗿𝗲𝗮𝗰𝗵. For patients and and leaders in gene therapy, 𝘵𝘩𝘦 𝘮𝘢𝘳𝘳𝘪𝘢𝘨𝘦 𝘰𝘧 𝘯𝘢𝘯𝘰𝘣𝘰𝘥𝘪𝘦𝘴 𝘸𝘪𝘵𝘩 𝘈𝘈𝘝 𝘷𝘦𝘤𝘵𝘰𝘳𝘴 𝘤𝘰𝘶𝘭𝘥 𝘳𝘦𝘷𝘰𝘭𝘶𝘵𝘪𝘰𝘯𝘪𝘻𝘦 𝘵𝘩𝘦 𝘵𝘢𝘳𝘨𝘦𝘵𝘪𝘯𝘨 𝘰𝘧 𝘴𝘱𝘦𝘤𝘪𝘧𝘪𝘤 𝘤𝘦𝘭𝘭𝘴, 𝘭𝘰𝘸𝘦𝘳 𝘵𝘩𝘦 𝘢𝘮𝘰𝘶𝘯𝘵 𝘰𝘧 𝘷𝘦𝘤𝘵𝘰𝘳 𝘯𝘦𝘦𝘥𝘦𝘥 𝘧𝘰𝘳 𝘴𝘺𝘴𝘵𝘦𝘮𝘪𝘤 𝘢𝘥𝘮𝘪𝘯𝘪𝘴𝘵𝘳𝘢𝘵𝘪𝘰𝘯, 𝘳𝘦𝘥𝘶𝘤𝘦 𝘰𝘧𝘧-𝘵𝘢𝘳𝘨𝘦𝘵 𝘦𝘧𝘧𝘦𝘤𝘵𝘴, 𝘢𝘯𝘥 𝘶𝘭𝘵𝘪𝘮𝘢𝘵𝘦𝘭𝘺 𝘪𝘮𝘱𝘳𝘰𝘷𝘦 𝘱𝘢𝘵𝘪𝘦𝘯𝘵 𝘰𝘶𝘵𝘤𝘰𝘮𝘦𝘴. If this precision delivery strategy proves effective in clinical settings, it would be a true game changer for our field. A new study maps out “𝗵𝗼𝘁𝘀𝗽𝗼𝘁” regions on the AAV (adeno-associated virus) capsid—formed by its VP1, VP2, and VP3 proteins—where nanobodies can be inserted without disrupting the virus. By engineering these hotspots, especially in VP2, scientists enabled AAVs to carry nanobodies that recognize markers like fibroblast activating protein (FAP)—a target overexpressed in certain cancers. What’s exciting: 𝗔𝘁 𝘁𝗵𝗲 𝗯𝗲𝘀𝘁 𝗰𝗮𝗽𝘀𝗶𝗱 𝘀𝗶𝘁𝗲, 𝗔𝗔𝗩𝘀 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗙𝗔𝗣 𝗻𝗮𝗻𝗼𝗯𝗼𝗱𝘆 𝗯𝗼𝗼𝘀𝘁𝗲𝗱 𝗶𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗙𝗔𝗣+ 𝗰𝗲𝗹𝗹𝘀 𝗯𝘆 𝘂𝗽 𝘁𝗼 𝟭𝟴-𝗳𝗼𝗹𝗱 𝘄𝗶𝘁𝗵 𝗺𝗶𝗻𝗶𝗺𝗮𝗹 𝗶𝗺𝗽𝗮𝗰𝘁 𝗼𝗻 𝗼𝗳𝗳-𝘁𝗮𝗿𝗴𝗲𝘁 𝗰𝗲𝗹𝗹𝘀. This means more payload gets exactly where it’s needed, reducing wasted vector and risks outside the intended tissue—even when dosing is lowered. The power multiplies when the team combined nanobody insertion with deletion of AAV's natural heparin-binding domain, known for liver targeting. This two-step engineering nearly eliminated off-target delivery to hepatocytes, a major safety concern for systemic gene therapies 𝗮𝘀 𝗵𝗮𝘀 𝗯𝗲𝗲𝗻 𝘀𝗲𝗲𝗻 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗿𝗲𝗰𝗲𝗻𝘁 𝗱𝗲𝗮𝘁𝗵𝘀 𝗶𝗻 𝗦𝗲𝗿𝗲𝗽𝘁𝗮'𝘀 𝗗𝗠𝗗 𝗽𝗿𝗼𝗴𝗿𝗮𝗺. Why does this matter? The "𝗽𝗹𝘂𝗴-𝗮𝗻𝗱-𝗽𝗹𝗮𝘆” approach means just swapping the nanobody can quickly retarget AAVs to virtually any cell type—hugely accelerating personalized gene medicines. 𝗜𝗳 𝘁𝗵𝗶𝘀 𝗺𝗼𝗱𝘂𝗹𝗮𝗿 𝗽𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝘁𝗮𝗿𝗴𝗲𝘁𝗶𝗻𝗴 𝗶𝘀 𝗽𝗿𝗼𝘃𝗲𝗻 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗹𝗶𝗻𝗶𝗰, 𝗶𝘁 𝗰𝗼𝘂𝗹𝗱 𝗯𝗲 𝗮 𝘁𝗿𝘂𝗲 𝗴𝗮𝗺𝗲 𝗰𝗵𝗮𝗻𝗴𝗲𝗿 𝗳𝗼𝗿 𝗼𝘂𝗿 𝗳𝗶𝗲𝗹𝗱, 𝗼𝗽𝗲𝗻𝗶𝗻𝗴 𝗱𝗼𝗼𝗿𝘀 𝗳𝗼𝗿 𝘀𝗺𝗮𝗿𝘁𝗲𝗿, 𝘀𝗮𝗳𝗲𝗿, 𝗮𝗻𝗱 𝗺𝗼𝗿𝗲 𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀. #GeneTherapy #AAV #Nanobody #TargetedDelivery #BiotechInnovation

🔬 Europe Must Accelerate Personalized Medicine or Risk Falling Behind Brussels, May 21st, 2025: The hot-off-the-press Nature Medicine article "Cancer treatment paradigms in the precision medicine era" – authored by precision oncology pioneers including Vivek Subbiah, MD, Razelle Kurzrock, Giuseppe Curigliano, and European Alliance for Personalised Medicine (EAPM) – presents both an exhilarating vision and an indictment. While the science of personalized cancer care advances at speed, Europe’s healthcare systems remain trapped in twentieth-century paradigms. ⚠️ The time for talk has passed; we need immediate, coordinated action to bridge this innovation gap. 🧭 The Innovation Chasm The article’s authors demonstrate how precision medicine is already transforming outcomes: ✅ Tumor-agnostic therapies like NTRK inhibitors achieving unprecedented response rates ✅ Early molecular profiling turning previously fatal cancers into chronic conditions ✅ Real-world evidence platforms accelerating life-saving approvals ❗ Yet, Europe continues to lag in implementation. While the U.S. has approved 10+ tumor-agnostic therapies, European patients face: ⏳ 18–24 month delays in EMA approvals vs. FDA 💸 Reimbursement paralysis in 70% of EU markets 🧪 Diagnostic deserts where comprehensive genomic profiling remains unavailable 🚧 Three Critical Barriers – And Solutions 📜 Regulatory Rigidity As Vivek Subbiah emphasizes, traditional RCTs are often inappropriate for rare targets – yet EMA maintains excessive requirements ✅ Solution: Implement the authors’ proposed "specialized pathways" for molecularly-defined cancers 🔬 Diagnostic Fragmentation Early profiling saves lives – yet only 5 EU countries systematically test at diagnosis ✅ Solution: Make NGS testing mandatory under the EU Cancer Plan with cross-border reimbursement 💾 Data Paralysis The PRIME-ROSE project proves pan-European collaboration works – but EHDS implementation remains sluggish ✅ Solution: Create fast-track oncology data corridors under EU4Health 📘 A Blueprint for Action The Nature Medicine authors provide the strategy. Now, Europe must execute: 🗓️ Before 2025: Harmonize tumor-agnostic approvals via ETAC (ESMO’s classifier) 🗓️ By 2026: Roll out precision medicine hubs under Europe’s Beating Cancer Plan and link EU4Health funding to genomic testing benchmarks ⏳ The Cost of Waiting Every year of delay means: 🧬 112,000+ Europeans dying from cancers with existing targeted therapies 📣 Our Call to EU Leaders 🧑⚖️ Regulators: Shorten approval timelines for biomarker-matched therapies 💼 Payers: Develop outcome-based contracts for precision medicines 🏛️ Governments: Fund cross-border molecular registries—now As the article concludes: "Precision medicine’s potential is limited only by our willingness to adapt." Europe must choose: lead the revolution—or watch as patients seek care elsewhere. Paolo, Nicola, Suzette, John Ph.D., FACMG, Josep MD, PhD, Marc Van den Bulcke, fabrice andre

🔇 Cell Therapy New publication Alert ⁉️ This research paper, published in #NatureBiomedicalEngineering, introduces a breakthrough platform called BROAD-CAR designed to overcome the primary obstacles of #CAR-T cell therapy in #solidtumors. ⁉️ The Challenge: The "Fortress" and the "Invisible" Enemy While CAR-T therapy has revolutionized blood cancer treatment, it often fails in solid tumors for two reasons: 👉 Immunosuppressive Environment: The tumor microenvironment (TME) acts like a fortress, suppressing T cells and exhausting them before they can work. 👉 Antigen Heterogeneity: Solid tumors are diverse; some cells lack the "target" (antigen) that CAR-T cells are programmed to find, allowing them to hide and lead to recurrence. 🖋️ The Solution: BROAD-CAR (Bacterial "Trojan Horses") Researchers engineered bacterial outer membrane vesicles (OMVs)—tiny, safe packages derived from bacteria—to act as a multi-functional delivery system. BROAD-CAR works through a sophisticated two-pronged strategy: ⚡ Breaking the Shield (Immunosuppression Reversal): The vesicles are modified to express high-affinity anti-#PDL1 antibodies. This blocks the "off switch" (PD-1/PD-L1 pathway) that tumors use to deactivate T cells, keeping the CAR-T cells active and aggressive. ⚡ Painting the Target (Antigen Decoration): The OMVs carry plasmids (genetic instructions) that they "deliver" directly into tumor cells. These instructions force even antigen-negative (invisible) tumor cells to express the target antigen (like HER2) on their surface. Essentially, the researchers "painted" a bullseye on the cells that were previously hiding. ⚡ Waking Up the Immune System: Because they are bacterial in origin, the vesicles naturally "alarm" the innate immune system, recruiting more "soldier" cells (M1 macrophages and NK cells) to the site. ⁉️ Why This Matters ☝ In mouse models of aggressive breast cancer, this platform demonstrated remarkable results: Enhanced Efficacy: It boosted CAR-T cell expansion and infiltration into the tumor. ☝ Total Coverage: It successfully eliminated tumors that were a mix of antigen-positive and antigen-negative cells, which normally escape standard CAR-T therapy. ☝ Prevention of Recurrence: The treatment inhibited tumor recurrence and metastasis. 👍 Safety: The platform showed a high level of biosafety with no significant damage to major organs. #Takeaway: By combining the immune-triggering power of bacteria with advanced genetic engineering, BROAD-CAR turns "cold" solid tumors into "hot" targets, ensuring no cancer cell—no matter how well it hides—is left behind. This could significantly broaden the range of cancers that CAR-T can effectively treat. #Celltherapy #CancerResearch #Immunotherapy #CART #Biotech #NatureBiomedicalEngineering #Innovation #Oncology #outermembranevesicles (OMVs)